Abstracts/Lang Gmcer 13 (1995) 323-356 335

group was 15 patients with non malignant lung diseases (8 patients with pulmonary tuberculosis, 3 patients with chronic obstructive pulmonary disease, 2 patients with pneumonia and 2 patients with chronic obstructive pulmonary disease combined with pulmonary tukrculosis).Resulls:TbemeansenunvalueofCYFRAZl-Iwas20.2 * 4.7 rig/ml in squamous cell carcinoma, 7.2 f 1.6 nglml in adenocarcinoma and 15.5 l 4.7 ngAnl in non-small cell lung cancer. The saum value 0fCYFRA 21-1 in control group was 1.7 M.5 @ml. All of the serum vahtes of 3 histologic types were signiticantly higher thanthatofcontrolgmup@~O.O1).TheserumvalueofCyFRA21-1 of squamous cell carcinoma was signiticantly higher than that of adermacinoma @ < 0.05). Serum value of CYFRA 21-1 in small cell lung-r was 2.9 * 0.9 rig/ml and not signilicantly different compared with control group. Using cut off value of 3.3 @ml, sensitivity and specilicity was 1 1. l%, 65.2% in small cell lung cancer, 70.0%. 62.5% in non-small cell lung cancer, 73.7Y* 75Y0 in squamous cell carcinoma and 63.6% 78.9% in adenocarcinoma, mspcctively. Conclusion: The serum levels of CYPM 2 l-1 may be u&id in diagnosis of non-small cell lung carcinoma, especially in squamous cell carcinoma with its high specificity.

Fibembmnchoscopic findings in 246 cases of central type of lung cancer Wang X-Y, Yang J-Q, Zhang G-D. Thnrgshmr 7kmor Ho@tal, Tmgshon. Chin J Clin Gncol 1995;22:467-9.

TWO hundred and forty-six patients with central type of lung cancer wxeexamimdwithfibembmdosmpy. Allthenmplasmswere.situated at the level of segmental lobular bronchi and centripetally. 6 1% of the tumors were located in the right lung and 39% on the let?. Upper lobes hosted 46.4% of the lesions and the lower lobes harboured 28% ofthe hunors. Pathologically thtee types wele rem- they wen squamous cell carcinoma (56.1%). small cell carcinoma (28%) and adeno- carcinoma (14.6Ye). Squamous cell carcinoma usually appeated as exophytic gmvth and tended to block the bronchial lumen. On the other hand, small cell carcinoma and adenocarcinoma were prone to infiltration. Endoscopically the former usually presented as local overgrowth of the mucous membrancc and the bronchial lumen in turn was natmwed; the latter was polypoid in form. And, the discoloration androughncssoftbelocalmucousmembtanceappeaMin12ofthem whose cheat film and CT scan weie negative for signs of-r. It is conch&d that repeated bronchoscopic ucamiaation may improve early diagnosis of the lung -.

Omsomucoid: Prealbumine ratio in lung cancer Charct J.C. Lepretm A. Watins J. Jounieaux V. Amn C. Chamt P Service de pneunwlogie, hopital de Rodeo. I rue Combarel. 12000 Rode; Ann Biol Clin 1995;53:131-4.

Lung cancer is a common patbologv wih high mortality rate due to late diagnosis. The 1987 TNM dassitication clearly detines the different steps and their prognosis. Although the prognostic value of some biological pamnuMs (nminly serum LDH, sodium aud/or albumin) has been established. these are not much used. We ahve pmspectively studied the serum levels of seven pmteins (RBP, prenlbumin, albumin, bansferrin, haptogkhin, otosomucoid, CRP) and we demonstrate the predominant value of preaRmnun for the establishment of the prognosis of lung cancer; determination oforosomucoid increases the prognostic value ofprealbumin. We contirm, for lung cancer, the prognostic value of the orosomucoid-prealbumln ratio, already known for other cancers.

Small peripheral lung carcinoma evabuted with incremental dynamic CT: R8diologic-pathologic correlation YamashitaK,h4atsunobeS,TakahashiR TsudaT,MatsumotoKMiki H et al. Department of RadioIogv. Shiga Health Insurance Hospital, 16-1, Fujimidai, Otsu 520. Radiology 1995;1%:401-8.

Purpose: To correlate incremental dynamic computed tomographic (CT) and pathologic findings in peripheral lung -r. Material and Methods: Lung lesions smaller than 3 cm in diameter were evaluated in 18 patients. CT values of the’ inner area of the nodule at plain CT and at 30 seconds, 2 minutes, and 5 minutes af&er administration of nonionic contrast material were calculated with incremental dynamic CT. Maximum attenuation was compared with pathologic type of lung carcinoma and with number of vessels and distribution of elastic fibers in the pathologic specimen. Results: Enhancement of all lesions was statistically sign&ant (P < .OOOl). Maximum attenuation of lung carcinomas correlated positively with number ofsmall vessels (diameter, 0.024.10 mm) (r = .77). Distribution of elastic fibers in the tumoral interstitium correlated with maximum attenuation (P = .04 between grades 1 and 3) and with number of small vessels (P = .Ol between grades l- 3; P = .008 between grades 1 and 3). Conclusion: Enhancement chaNctcritics of lung carcinomas retleet the number of small tumoral vessels and the distribution of elastic fibers in the tumorsJ interstitium.

Enzymolinked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S et al. Growth Factor Division, National Cancer Center. Research Institute, 5-I-l Tsukiji, Chuo-ku, Tokyo IO4. Jpn J Cancer Res 1995;86:698-705.

Our previous study demonstrated that pro-gastrin-releasing peptide(3 l-98). or ProGRP, is a specific tumor marker in patients with small cell lung carcinoma (SCLC). Using a newly developed, highly sensitive enzyme-linked inununosorbent assay (ELISA) for ProGRP, we analyzed 1,446 samples including those obtained from 478 lung cancer patients to evaluate the clinical usetidncss ofthis ELISA. Several properties indicated that ProGRP is a useful tumor marker for SCLC. First, ProGRP was specifically elevated in SCLC patients. In non-SCLC patients and patients with non-tumorous lung diseases, its serum level was very rareIy elevated. Secondly, ProGRP was a reliable marker, in terms of the marked elevation of serum PmGRP levels in SCLC patients. Thirdly, serum ProGRF levels were elevated in SCLC patients even at a relatively early stage of this disease. Fourthly, changes in the senun ProGRP level showed an excellent correlation with the therapeutic responses in SCLC patients. Neuron-specific enolase (NSE) is acccptcd as a tumor marker of SCLC patients. W~tb the aim of mmparing ProGRP and NSE as tumor markers for SCLC patients, we measured serum NSE levels in all samples collected in the present study. We found that PKIGRP was superior to NSE in tenns of sensitivity, specificity and reliability. Therefore, we consider that ProGRP can play a major role as a clinical tumor marker for SCLC patients.

Survival of stage I lung cancer p8tients with previous or subsequent primuy 4-t neoplasms Mrsiljev OA, Kartchenko VP, Koozmine IV Moscow Res. inst. of Diagnosis&rg.; Profsojuznaya str. 86, Moscow. Radio1 Oncol 1995;29: 148-52.

From1%5to19902161patientsunderwentthecompleteresection for lung cancer. In 910 cases stage I was histologically proved. pT1 - 375 (41%). pT2 - 532 (58,7%). There were 90.9% cases observed for more then 5 years, 60.2% - 10 years. Ninety-six (10,6%) patients were